Terms: = Liver cancer AND MSN, P26038, 4478, ENSG00000147065 AND Diagnosis
6 results:
1. ALP-Activated Chemiluminescence PDT Nano-Platform for liver cancer-Specific Theranostics.
Fan N; Li P; Wu C; Wang X; Zhou Y; Tang B
ACS Appl Bio Mater; 2021 Feb; 4(2):1740-1748. PubMed ID: 35014520
[TBL] [Abstract] [Full Text] [Related]
2. Application of Abdominal Imaging Based on Nano Drug Delivery System for diagnosis and Treatment of liver cancer.
Fan Z; Liu Q; Lu F; Dong Z; Gao P
J Nanosci Nanotechnol; 2021 Feb; 21(2):824-832. PubMed ID: 33183413
[TBL] [Abstract] [Full Text] [Related]
3. Diagnostic imaging of hepatocellular carcinoma at community hospitals and their tertiary referral center in the era of LI-RADS: a quality assessment study.
Chan A; Sertic M; Sammon J; Kim TK; Jang HJ; Guimaraes L; O'Malley M; Khalili K
Abdom Radiol (NY); 2019 Dec; 44(12):4028-4036. PubMed ID: 31555846
[TBL] [Abstract] [Full Text] [Related]
4. Mucin-1-Antibody-Conjugated Mesoporous Silica Nanoparticles for Selective Breast cancer Detection in a Mucin-1 Transgenic Murine Mouse Model.
Dréau D; Moore LJ; Alvarez-Berrios MP; Tarannum M; Mukherjee P; Vivero-Escoto JL
J Biomed Nanotechnol; 2016 Dec; 12(12):2172-2184. PubMed ID: 28522938
[TBL] [Abstract] [Full Text] [Related]
5. Expression Analysis of Previously Verified Fecal and Plasma Dow-regulated MicroRNAs (miR-4478, 1295-3p, 142-3p and 26a-5p), in FFPE Tissue Samples of CRC Patients.
Ghanbari R; Rezasoltani S; Hashemi J; Mohamadkhani A; Tahmasebifar A; Arefian E; Mobarra N; Asadi J; Nazemalhosseini Mojarad E; Yazdani Y; Knuutila S; Malekzadeh R
Arch Iran Med; 2017 Feb; 20(2):92-95. PubMed ID: 28193082
[TBL] [Abstract] [Full Text] [Related]
6. Decreased expression of fecal miR-4478 and miR-1295b-3p in early-stage colorectal cancer.
Ghanbari R; Mosakhani N; Asadi J; Nouraee N; Mowla SJ; Poustchi H; Malekzadeh R; Knuutila S
Cancer Biomark; 2015; 15(2):189-95. PubMed ID: 25519020
[TBL] [Abstract] [Full Text] [Related]
